Please note, we are currently updating the 2018 Journal Metrics.
Aims and Scope
Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.
Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.
The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.
The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.
Enhanced Digital Features
Pulmonary Therapy offers a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include other enhanced digital features including (but not limited to) slide sets, videos, video abstracts, podcasts, infographics and animations. Adis can create digital features for you, or you can submit your own. All these enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research. For questions relating specifically to these features, please contact email@example.com.
Plain Language Summaries
Articles published in Pulmonary Therapy may be accompanied by plain language summaries to assist in understanding important medical advances. Both the enhanced digital features and plain language summaries can help to reach a broader audience thus supporting the effective dissemination of research.
Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of $4500/ €4000. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without the Rapid Service Fee (pending peer review) for every three reviews completed per calendar year. All articles are published open access.
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.
We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please follow the link for further information on preprint sharing:
Pulmonary Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
For more information about the journal, including pre-submission enquiries, please contact firstname.lastname@example.org.
- Journal Title
- Pulmonary Therapy
- Volume 1 / 2015 - Volume 5 / 2019
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
To view the rest of this content please follow the download PDF link above.